On Oct. 23, 2020, the U.S. FDA authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford coronavirus vaccine in the U.S. following the trials restarting in the UK, Brazil, South Africa and Japan.

On Sept. 6, a standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by an independent committee. The FDA has now reached the same conclusion as other international regulators, who have deemed that the trials are safe to resume.